CN107126485A - 一种辅助改善睡眠的中药组合物及其制备方法和应用 - Google Patents
一种辅助改善睡眠的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN107126485A CN107126485A CN201710229655.XA CN201710229655A CN107126485A CN 107126485 A CN107126485 A CN 107126485A CN 201710229655 A CN201710229655 A CN 201710229655A CN 107126485 A CN107126485 A CN 107126485A
- Authority
- CN
- China
- Prior art keywords
- parts
- sleep
- chinese medicine
- medicine composition
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 39
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 19
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 19
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 241000205407 Polygonum Species 0.000 claims abstract description 18
- 239000009636 Huang Qi Substances 0.000 claims abstract description 17
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 16
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 16
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 16
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 13
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 13
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 13
- 235000005412 red sage Nutrition 0.000 claims abstract description 13
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 12
- 235000020234 walnut Nutrition 0.000 claims abstract description 12
- 244000241872 Lycium chinense Species 0.000 claims abstract description 11
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 9
- 230000006872 improvement Effects 0.000 claims abstract description 7
- 244000000231 Sesamum indicum Species 0.000 claims abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 240000007049 Juglans regia Species 0.000 claims abstract 3
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract 3
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 abstract description 26
- 241000256856 Vespidae Species 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 18
- 210000000952 spleen Anatomy 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 13
- 229960000796 barbital sodium Drugs 0.000 abstract description 12
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 abstract description 12
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 abstract description 12
- 230000002936 tranquilizing effect Effects 0.000 abstract description 11
- 230000004620 sleep latency Effects 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000002557 soporific effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000012937 correction Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 17
- 240000008866 Ziziphus nummularia Species 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 206010022437 insomnia Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000207961 Sesamum Species 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 10
- 241000724115 Ziziphus lotus Species 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 241000758789 Juglans Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000000147 hypnotic effect Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000028527 righting reflex Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 206010003084 Areflexia Diseases 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- -1 oxygen radical Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 244000241838 Lycium barbarum Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 241000345998 Calamus manan Species 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960005143 amobarbital sodium Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 108700020142 mouse tocopherol-associated Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种辅助改善睡眠的中药组合物及其制备方法和应用。所述的辅助改善睡眠的中药组合物由以下重量份的原料组成:核桃仁15‑65份、酸枣仁15‑65份、丹参5‑55份、刺五加5‑35份、夜交藤5‑35份、黄芪5‑15份、莲子5‑15份、大枣5‑35份、枸杞子5‑35份、芝麻5‑15份、葡萄皮5‑15份、乌梅5‑15份、山楂5‑15份。经动物实验证明,本发明的高、中剂量的受试物均能辅助延长小鼠戊巴比妥钠睡眠时间和显著缩短小鼠巴比妥钠睡眠潜伏时间,但各剂量组均无直接促使动物睡眠作用,以此推广可作为改善人类睡眠的保健品,从而明显提高人体生命质量。本发明组方寒温并用,消补同施,补正不碍邪,肝脾肾阴阳兼顾,脾健自能运湿,具有养心安神、镇静催眠、活血通络、滋补肝肾、益气健脾之功。
Description
技术领域
本发明涉及一种中药组合物及其制备方法和应用,具体涉及一种辅助改善睡眠的中药组合物及其制备方法和应用。
背景技术
失眠是指患者对睡眠时间和/或质量不满足并影响日间社会功能的一种主观体验。随着生活节奏加快、工作压力增大,现如今失眠现象普遍存在。流行病学调查结果显示青中年人群失眠患病率为10%~20%,老年人失眠患病率高达35%~50%。我国目前睡眠不良者高达5亿人,失眠已成为困扰很多人的身心疾病,严重影响工作和生活质量。人的生命旅途中,几乎有1/3的时间是在睡眠中度过的,睡眠就像食物和水,是我们每一个人生存的生理需求,也是一种养生需要。“睡眠良好”是世界卫生组织对健康的十大标准之一,由此可见睡眠对于健康非常重要。
导致失眠常见原因有大脑睡眠功能紊乱,躯体疾病,精神障碍,药物滥用等,失眠常与其他疾病同时发生,有时很难确定这些疾病与失眠之间的因果关系,近年来提出共病性失眠(comorbidinsomnia)的概念,用以描述那些同时伴随其他疾病的失眠。人体各种疾病和/或心理压力大导致精神紧张、忧虑、用脑过度,都会使大脑神经功能失调,造成淤血气滞、阻滞经络引发失眠。
中医认为失眠是由于情志、饮食内伤,病后及年迈,禀赋不足,心虚胆怯等病因引起心神失养或心神不安,从而导致经常不能获得正常睡眠为特征的一类病症。主要表现为睡眠时间、睡眠深度的不足以及不能消除疲劳、恢复体力与精力,轻者入睡困难,重则彻夜不寐。虽不属于危重疾病,但常妨碍工作、学习和生活,并加重或诱发心悸、胸痹、眩晕、中风等病征。传统改善睡眠的研究多集中在镇静催眠药、褪黑素等方面,由于此类药物不良反应多、依从性差、停药后戒断反应等相关因素,长期服用存在一定耐药性,制约了在临床中的使用。但对于一部分失眠患者,中药或西药的药物治疗是必要的。中药较西药作用缓和,毒性较弱,但中药并非完全安全无毒,《素问》中提出“大毒治病十去其六,常毒治病十去其七,小毒治病十去其八,无毒治病十去其九”,中药有效成分提取制剂在疗效提高的同时毒性也在增加。因此,发明一种改善睡眠的中药组合物意义尤为重要。
发明内容
针对现有技术中的不足,本发明的目的在于提供一种辅助改善睡眠的中药组合物及其制备方法和应用。
为达到上述目的,本发明采用的技术手段为:
一种辅助改善睡眠的中药组合物,由以下重量份的原料组成:核桃仁15-65份、酸枣仁15-65份、丹参5-55份、刺五加5-35份、夜交藤5-35份、黄芪5-15份、莲子5-15份、大枣5-35份、枸杞子5-35份、芝麻5-15份、葡萄皮5-15份、乌梅5-15份、山楂5-15份。
优选的,所述的辅助改善睡眠的中药组合物,由以下重量份的原料组成:核桃仁40份、酸枣仁40份、丹参30份、刺五加20份、夜交藤20份、黄芪10份、莲子10份、大枣20份、枸杞子20份、芝麻10份、葡萄皮10份、乌梅10份、山楂10份。
发明人经过大量的研究和实验,得到了本发明中药组合物的配方,通过各原料的协同作用,起到很好的功效,其中,各原料组分功效如下:
核桃仁:核桃仁中富含磷脂,对脑神经有很好保健作用,其还含有不饱和脂肪酸,具有防治动脉硬化的功效。中医认为核桃性温、味甘,归肾、肺、大肠经,有健胃、补血、润肺、养神等功效,可缓解人体神经衰弱、健忘、失眠、多梦和饮食不振。
酸枣仁:酸枣仁中含有的酸枣仁总皂苷、总生物碱及不饱和脂肪酸具有镇静催眠的作用,酸枣仁可延长大脑慢波深睡眠时间,增加深睡发作频率发挥催眠作用;同时酸枣仁可通过降低额叶中的多巴胺和五羟色胺的含量发挥抗抑郁作用。中医认为酸枣仁味甘、酸,性平,具有养肝宁心、敛汗生津之功效,归心、肝经,可用于治疗神经衰弱、失眠多梦、虚烦不眠、惊悸。
丹参:丹参可通过抑制脑中cAMP磷酸二酯酶、升高cAMP水平抑制中枢神经系统发挥镇静作用。丹参中的丹酚酸对皮层神经元有保护作用,能抑神经细胞凋亡。同时丹参酮具有明显的抗氧化作用,能抑制脑中脂质过氧化,减少脑损伤。此外丹参酮具有抗动脉粥样硬化、抗血小板凝聚作用,其可通过拮抗心肌缺血时的线粒体钙超载发挥保护心肌的作用。中医认为丹参味苦,微寒,具有安神宁心、活血祛瘀的功效,归心、肝二经。可用于治疗胸痹心痛、心神不宁等症。
以上3药共为君药,起到镇静催眠、养心安神、活血祛瘀、健脑益脑的功效。
刺五加:刺五加可调节中枢神经系统兴奋和抑制过程,缩短入睡时间,增加睡眠时间和深度;其还可增加心肌血流量,降低冠脉阻力,减少心肌耗氧量,扩张脑血管,改善大脑供血;此外,其所含刺五加皂苷具有促进脑细胞代谢和修复的作用。中医认为刺五加味辛,苦涩,微甘,性温,归脾、肾、心经,具有益气健脾,补肾安神之功效。可用于治疗心脾不足,失眠多梦,是治疗神经衰弱的一种疗效显著的药物。
夜交藤:夜交藤中含有夜交藤苷、夜交藤蒽醌及夜交藤黄酮均有一定镇静催眠和中枢神经抑制作用,因此可以改善睡眠。夜交藤为蓼科植物何首乌的藤茎或带叶的藤茎,别名:首乌藤。中医认为夜交藤,味甘,性平;归心、肝经,具有养心安神,滋阴养血,补肾益肝,祛风通络之功效。可用于治疗失眠多汗,血虚身痛,痈疽等症。
黄芪:黄芪可通过调节细胞内cAMP、cGMP含量促进机体生理代谢增强,从而改善大脑活力。黄芪能加强心脏收缩力,强心,增加脑及全身组织的供血量。同时,黄芪对外周血管尤其脑血管有扩张作用,间接改善脑的供血,从而改善睡眠。此外,黄芪中富含黄芪多糖可降低组织耗氧量,增强机体抗疲劳能力。中医认为黄芪,味甘,性平;入肺、脾二经;具有益气固表之功效。
莲子:莲子中所含莲子碱、芳香甙等活性成分,可促进胰岛素分泌,进而增加五羟色胺含量促发入睡,从而发挥镇静催眠的作用。中医认为莲子味甘、涩,性平,归脾、肾、心经,具有补心益脾、养血安神等功效,可用于治疗脾虚泄泻,心悸失眠。
以上4药共为臣药,其中刺五加、夜交藤和莲子共同辅助君药发挥镇静安神的功效,刺五加和黄芪共同辅助君药养心补血的功效,夜交藤和黄芪共同辅佐君药发挥活血通络的功效。4味药并用,养心安神通络,辅助改善失眠。
大枣:大枣中所含cAMP可参与调节多种生理过程,能舒张血管平滑肌、改善肝功能、增强心肌收缩力、改善心肌营养。大枣中富含大枣多糖,具有抗氧化、抗衰老活性,能帮助清除体内多余氧自由基;其次,大枣多糖能有效改善造血功能及红细胞能量代谢。大枣中所含黄酮及糖苷类具有血管舒张和抗血小板凝胶作用,并能有效清除自由基,抑制生物膜多不饱和脂肪酸发生过氧化,与大枣中的生物碱一样具有镇静作用,延长深度睡眠时长。中医认为大枣味甘,性温,入脾、胃经,有补中益气,养血安神的功效,可用于治疗脾胃虚弱,气血不足,心悸怔忡,并能减少其他药物的毒副作用。
枸杞:枸杞子富含枸杞多糖,其能提高机体抗氧化系统活性,进而增加机体抗氧化能力,抑制细胞脂质过氧化作用。同时,枸杞中富含大量微量元素,可营养机体,滋养神经。中医认为枸杞子,味甘,平;归肝肾二经,具有补肾益精,养肝明目,润肺生津之功效。
芝麻:芝麻含有丰富的不饱和脂肪酸、维生素E、芝麻含有大量的脂肪酸、蛋白质、糖类、维生素A、维生素E、卵磷脂、钙、铁、镁等营养成分,芝麻中的亚油酸有调节胆固醇的作用,芝麻中含有丰富的维生素E,能增加机体抗氧化能力,此外芝麻中的芝麻素具有健脑防早衰的作用。中医认为芝麻味甘、性平,入肝肾肺脾经,具有补五气,填脑髓,安神镇静,补血明目、益肝养发、抗衰老之功效。
葡萄皮:葡萄皮能降低人体血清胆固醇水平,降低血小板的凝聚力;葡萄皮中的类黄酮、白藜芦醇和花青素均为强力抗氧化剂,可抗衰老,并可清除体内自由基;同时葡萄皮对神经衰弱、疲劳过度大有裨益。中医认为葡萄味甘酸,性平。入肺、脾、肾经。具有补气血,强筋骨之功效。可治气血虚弱,心悸盗汗。
乌梅:乌梅能有效清除体内氧自由基,发挥抗氧化作用,其水煎液具有抗惊厥作用。中医认为乌梅性温,味酸涩,有生津、止渴、敛肺、涩肠等功效。
山楂:山楂含有大量的胡萝卜素、钙质、碳水化合物、山楂酸、果胶、维生素、黄酮类化合物。具有健胃止痢,增强心肌收缩力、增加冠脉流量、抗心律不齐、降压、降血脂、抗菌等作用。中医认为山楂味酸、甘,性微温。归脾、胃、肝经。具有消食健胃,行气散瘀,化浊降脂之功效。可用于胸痹心痛。
以上6药共为佐药,其中大枣、葡萄皮、枸杞子、乌梅和芝麻共同发挥抗氧化抗衰老作用,增强机体免疫力,抗疲劳功效;葡萄皮和大枣共同辅助君臣药养血补血作用;芝麻和山楂营养丰富,滋养全身;大枣、芝麻和乌梅共同辅助君臣药发挥镇静安神作用。6味药并用,安神镇静,活血化瘀,补心益脾,滋补肝肾,润肺生津,完善中药组合物配比,助君臣药养心安神镇静之效。
上述13种成分均具有较好的改善睡眠作用,可协同发挥作用,本发明配方具有补肾养心、养血安神、疏肝活血的功效,能起到镇静催眠、益智健脑等作用,对于神经衰弱、失眠健忘等病症具有很好的治疗作用,通过提高睡眠质量可减缓人体衰老和增强免疫力。
本发明进一步提供了一种制备所述的辅助改善睡眠的中药组合物的方法,包括以下步骤:称取所述重量份的各原料,并清洗去除杂质,于40-60℃烘3-7小时后将各原料磨成50-70目细粉,杀菌,混合后即得。
将所述的辅助改善睡眠的中药组合物用于制备改善睡眠的保健品或药物。
将所述的辅助改善睡眠的中药组合物制备成中药丸剂、散剂、片剂或胶囊剂。
相对于现有技术,本发明的有益技术效果在于:
本发明以祖国医学基础理论为指导方针,结合临床经验精构而成,由核桃仁、酸枣仁、丹参、刺五加、夜交藤、黄芪、莲子、大枣、枸杞子、芝麻、葡萄皮、乌梅、山楂等13味药物组成,将其制成中药丸剂、散剂、片剂、胶囊剂等多种剂型,方法简单易行,易于被患者接受,解决了因药物味数较多、口感不好、人体日常摄取达不到方剂要求的问题。本方以药食同源理论为依据全部为入药典的食药兼用品及食品组成,在提倡健康饮食和改善生活方式的基础上,食疗可为大众所接受,矫正失眠效能温和,安全无毒,具有明显的优势。
经试验,本发明的中药组合物具有改善小鼠睡眠的作用,以此推广可作为改善人类睡眠的保健品,从而明显提高人体生命质量。本发明组方寒温并用,消补同施,补正不碍邪,肝脾肾阴阳兼顾,脾健自能运湿,具有养心安神、镇静催眠、活血通络、滋补肝肾、益气健脾之功。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例1一种辅助改善睡眠的中药组合物及其制备方法
称取如下重量份的原料:核桃仁40份、酸枣仁40份、丹参30份、刺五加20份、夜交藤20份、黄芪10份、莲子10份、大枣20份、枸杞子20份、芝麻10份、葡萄皮10份、乌梅10份、山楂10份。
将各原料清洗去除杂质,于50-60℃烘5小时后将各原料磨成60目左右的细粉,杀菌,混合后即得该中药组合物。
实施例2一种辅助改善睡眠的中药组合物及其制备方法
称取如下重量份的原料:核桃仁20份、酸枣仁20份、丹参10份、刺五加10份、夜交藤10份、黄芪5份、莲子5份、大枣10份、枸杞子10份、芝麻5份、葡萄皮5份、乌梅5份、山楂5份。
将各原料清洗去除杂质,于40-60℃烘5小时后将各原料磨成60目左右的细粉,杀菌,混合后即得该中药组合物。
实施例3一种辅助改善睡眠的中药组合物及其制备方法
称取如下重量份的原料:核桃仁60份、酸枣仁60份、丹参50份、刺五加30份、夜交藤30份、黄芪15份、莲子15份、大枣30份、枸杞子30份、芝麻15份、葡萄皮15份、乌梅15份、山楂15份。
将各原料清洗去除杂质,于40-60℃烘5小时后将各原料磨成60目左右的细粉,杀菌,混合后即得该中药组合物。
实施例4一种辅助改善睡眠的中药组合物的应用
将实施例1制备的中药组合物按照常规制法制成中药丸剂、散剂、片剂、胶囊剂或其他制剂。
成人体重以60kg计,该样品推荐剂量为每人每日8.0g,相当于0.133g/kg·bw。辅助戊巴比妥钠或巴比妥钠服用。
实施例5本发明产品的功效性试验
1、实验材料
实验动物:选健康成年ICR雄性小鼠192只,体重18-22g,购自北京维通利华实验动物技术有限公司,实验动物许可证号:SCXK(京)2012-0001。将小鼠在SPF级动物实验中心于屏障环境饲养(许可证号:SYXK(黑)2011007),将温度设定为21℃~23℃,湿度为55%~58%。试验动物所用的清洁级饲料购自北京科澳协力饲料有限公司(许可证号:SCXK(京)2009-0012)。将小鼠混笼饲养。
实验仪器:秒表、MP3002-电子天平、小鼠灌胃针、注射器、镊子、注射器。
受试物:实施例1中制备得到的辅助改善睡眠的中药组合物,为棕褐色粉末,感官检查未见异常。
实验试剂:戊巴比妥钠、巴比妥钠、生理盐水、蒸馏水。
2、实验方法
1.1动物分组
于屏障系统下以饲料喂饲动物观察3天后,将192只雄性小鼠分为四个改善睡眠功能组:
改善睡眠功能一组:选择健康雄性小鼠48只,体重18~22g,进行直接睡眠试验。
改善睡眠功能二组:选择健康雄性小鼠48只,体重18~22g,进行延长戊巴比妥钠睡眠时间试验。
改善睡眠功能三组:选择健康雄性小鼠48只,体重18~22g,进行戊巴比妥钠阈下剂量催眠试验。
改善睡眠功能四组:选择健康雄性小鼠48只,体重18~22g,进行小鼠巴比妥钠睡眠潜伏期试验。
每组改善睡眠功能组按体重随机分为4组,每组12只,分为高、中、低三个剂量组及空白对照组,设高、中、低剂量分别3.999g/kg·bw(相当于人推荐用量的30倍))、1.333g/kg·bw(相当于人推荐用量的10倍)、0.667g/kg·bw(相当于人推荐用量的5倍),高、中、低剂量分别按199.95mg、66.62mg、33.35mg/mL浓度配置药液,各组动物均按20ml/kg·bw灌胃容积进行灌胃,空白对照组灌胃等容积蒸馏水。
1.1.1直接睡眠试验
末次灌胃受试物,阴性对照组给予同体积蒸馏水后,观察是否出现睡眠现象。睡眠以翻正反射消失为指标,当小鼠置于背卧位时,能立即翻正身位,如超过30-60秒不能翻正者,即认为翻正反射消失,进入睡眠。翻正反射恢复即为动物觉醒,翻正反射消失至恢复这段时间为动物睡眠时间,记录各组小鼠入睡动物数及睡眠时间。
1.1.2延长戊巴比妥钠睡眠时间试验
做正式试验前先进行预实验,确定使动物100%入睡,但又不使睡眠时间过长的剂量,以此剂量做正式实验。动物末次给予蒸馏水及不同浓度受试物后,出现峰作用前10-15分钟,给各组动物腹腔注射戊巴比妥钠,注射剂量为50mg/kg·bw,注射量为1.0ml/100g·bw,用生理盐水配制戊巴比妥钠的浓度为5mg/ml,以翻正反射消失为指标,观察受试物能否延长戊巴比妥钠诱导睡眠时间。
1.1.3戊巴比妥钠阈下剂量催眠试验
做正式实验前先进行预实验,确定戊巴比妥钠阈下剂量为25mg/kg·bw,注射量为1.0ml/100g·bw,即80-90%小鼠翻正反射不消失的戊巴比妥钠最大阈下剂量。动物末次给予蒸馏水及不同浓度受试物后,出现峰作用前10-15分钟,给各组动物腹腔注射戊巴比妥钠最大阈下催眠剂量,记录30分钟内入睡动物数(翻正反射消失达1分钟以上者)。
1.1.4巴比妥钠睡眠潜伏期试验
做正式实验前先进行预实验,确定使动物100%入睡,但又不使睡眠时间过长的巴比妥钠的剂量,用此剂量正式实验。动物末次给予蒸馏水及不同浓度受试物20分钟后,给各组动物腹腔注射巴比妥钠,注射剂量为300mg/kg·bw,注射量为1.0ml/100g·bw,配制巴比妥钠的浓度为30mg/ml,用生理盐水配制此浓度巴比妥钠20ml,以翻正反射消失为指标,观察受试物对巴比妥钠睡眠潜伏期的影响。
1.2实验数据与结果
试验数据由“双人双份录入数据”,由两人分别独立录入同一批数据资料,即采用双重录入法,然后进行两个数据库的比较,不一致的地方对照原始数据修改,进行复核更正,直到两份数据库完全一致。采用SPSS17.0软件对所有试验数据进行统计学分析,计量资料采用方差分析,进行方差齐性检验,
多个试验组和1个对照组间均数两两比较,用Dunnett t检验,对于资料不符合正态分布进行数据转换,使之服从正态分布,然后对转换后四位数据采用方差分析,转换后仍未达到正态或资料方差不齐,采用非参数检验。睡眠时间及睡眠潜伏期采用方差分析,入睡动物数采用卡方检验,每个剂量组分别与空白对照组比较,以P<0.05视为有统计学意义。
1.2.1受试物对小鼠体重的影响
给予各实验组小鼠不同剂量受试物30天后,测量小鼠体重变化,对小鼠体重的影响分别见表1-4。
表1受试物对小鼠体重的影响(改善睡眠功能一组)
表2受试物对小鼠体重的影响(改善睡眠功能二组)
表3受试物对小鼠体重的影响(改善睡眠功能三组)
表4受试物对小鼠体重的影响(改善睡眠功能四组)
由表1-4结果可见,改善睡眠功能各个实验组中,高、中、低三个受试物剂量动物的初始体重和终末体重与阴性对照组相比较均无显著性差异(P>0.05),说明本实验条件下受试物对小鼠体重增长无影响。
1.2.2受试物对小鼠直接睡眠时间的影响
经口给予改善睡眠功能一组小鼠不同剂量受试物30天后,各剂量组动物直接睡眠时间结果见表5。
表5受试物对小鼠直接睡眠时间的影响
注:与空白对照组相比P>0.05
从表5结果可见,给予受试物30天后,各剂量组动物均未出现直接睡眠现象。
1.2.3受试物对小鼠延长戊巴比妥钠睡眠时间影响
经口给予改善睡眠功能二组小鼠不同剂量受试物30天后,各剂量组动物延长戊巴比妥钠睡眠时间测定结果见表6。
表6受试物对小鼠延长戊巴比妥钠睡眠时间的影响
注:*与空白对照组相比P<0.05
由表6结果可见,给予受试物30天后,受试物中、高剂量组小鼠的睡眠时间显著延长(p<0.05)。
1.2.4受试物对小鼠戊巴比妥钠阈下剂量催眠发生率的影响
经口给予改善睡眠功能三组小鼠不同剂量受试物30天后,各剂量组动物戊巴比妥钠阈下剂量催眠发生率测定结果见表7。
表7受试物对小鼠戊巴比妥钠阈下剂量催眠发生率的影响
注:与空白对照组相比P>0.05
从表7结果可见,给予受试物30天后,各剂量组动物戊巴比妥钠阈下剂量催眠发生率无显著差异。
1.2.5受试物对小鼠巴比妥钠睡眠潜伏时间影响
经口给予改善睡眠功能四组小鼠不同剂量受试物30天后,各剂量组动物巴比妥钠睡眠潜伏时间测定结果见表8。
表8受试物对小鼠巴比妥钠睡眠潜伏时间的影响
注:*与空白对照组相比P<0.05
由表8结果可见,给予受试物30天后,受试物中、高剂量组小鼠的睡眠潜伏期时间较空白对照组显著缩短(p<0.05)。
1.3实验结论
本实验以0.133、1.333、3.999g/kg·bw不同剂量的受试物灌胃小鼠30天,以注射蒸馏水作对照组,实验结果显示,高、中剂量的受试物均能辅助延长小鼠戊巴比妥钠睡眠时间和显著缩短小鼠巴比妥钠睡眠潜伏时间,但各剂量组均无直接促使动物睡眠作用。根据《保健食品检验与评价技术规范》2003年版,本发明的受试物确实具有改善睡眠的作用。
Claims (5)
1.一种辅助改善睡眠的中药组合物,其特征在于,由以下重量份的原料组成:核桃仁15-65份、酸枣仁15-65份、丹参5-55份、刺五加5-35份、夜交藤5-35份、黄芪5-15份、莲子5-15份、大枣5-35份、枸杞子5-35份、芝麻5-15份、葡萄皮5-15份、乌梅5-15份、山楂5-15份。
2.如权利要求1所述的辅助改善睡眠的中药组合物,其特征在于,由以下重量份的原料组成:核桃仁40份、酸枣仁40份、丹参30份、刺五加20份、夜交藤20份、黄芪10份、莲子10份、大枣20份、枸杞子20份、芝麻10份、葡萄皮10份、乌梅10份、山楂10份。
3.一种制备如权利要求1或2所述的辅助改善睡眠的中药组合物的方法,其特征在于,包括以下步骤:称取所述重量份的各原料,并清洗去除杂质,于40-60℃烘3-7小时后将各原料磨成50-70目细粉,杀菌,混合后即得。
4.权利要求1或2所述的辅助改善睡眠的中药组合物在制备改善睡眠的保健品或药物中的应用。
5.将权利要求1或2所述的辅助改善睡眠的中药组合物制备成中药丸剂、散剂、片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710229655.XA CN107126485B (zh) | 2017-04-10 | 2017-04-10 | 一种辅助改善睡眠的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710229655.XA CN107126485B (zh) | 2017-04-10 | 2017-04-10 | 一种辅助改善睡眠的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107126485A true CN107126485A (zh) | 2017-09-05 |
CN107126485B CN107126485B (zh) | 2021-02-19 |
Family
ID=59716836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710229655.XA Active CN107126485B (zh) | 2017-04-10 | 2017-04-10 | 一种辅助改善睡眠的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107126485B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494498A (zh) * | 2020-03-23 | 2020-08-07 | 哈尔滨医科大学 | 一种辅助睡眠植物饮料及其制备方法和应用 |
CN111820414A (zh) * | 2020-08-03 | 2020-10-27 | 国珍健康科技(北京)有限公司 | 一种改善睡眠的保健食品及其制备方法 |
CN112956664A (zh) * | 2021-03-27 | 2021-06-15 | 黑龙江中医药大学 | 一种有助于改善睡眠功能的复合型果糕及其制备方法 |
CN113730511A (zh) * | 2021-09-17 | 2021-12-03 | 吉首大学 | 一种安神助眠的杜仲雄花配方组合物及其应用 |
CN114081171A (zh) * | 2020-08-09 | 2022-02-25 | 辽宁医学诊疗科技研发中心有限公司 | 一种具有辅助改善睡眠作用的功能性食品组合物 |
CN114190505A (zh) * | 2021-12-15 | 2022-03-18 | 哈尔滨健领医疗科技有限公司 | 一种助眠固体饮料及其制备方法 |
CN115521883A (zh) * | 2022-02-16 | 2022-12-27 | 广东益可维生物技术有限公司 | 一种具有缓解压力和改善睡眠功能的益生菌 |
CN116474060A (zh) * | 2022-01-13 | 2023-07-25 | 青岛百食膳康中医药科技有限公司 | 一种平衡阴阳改善睡眠的中药组合物、产品及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103263494A (zh) * | 2013-04-18 | 2013-08-28 | 威海东宝制药有限公司 | 一种具有安神助眠功效的中药保健品 |
-
2017
- 2017-04-10 CN CN201710229655.XA patent/CN107126485B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103263494A (zh) * | 2013-04-18 | 2013-08-28 | 威海东宝制药有限公司 | 一种具有安神助眠功效的中药保健品 |
Non-Patent Citations (1)
Title |
---|
施洪飞等: "安神益智类药膳配方统计分析", 《扬州大学烹饪学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494498A (zh) * | 2020-03-23 | 2020-08-07 | 哈尔滨医科大学 | 一种辅助睡眠植物饮料及其制备方法和应用 |
CN111820414A (zh) * | 2020-08-03 | 2020-10-27 | 国珍健康科技(北京)有限公司 | 一种改善睡眠的保健食品及其制备方法 |
CN114081171A (zh) * | 2020-08-09 | 2022-02-25 | 辽宁医学诊疗科技研发中心有限公司 | 一种具有辅助改善睡眠作用的功能性食品组合物 |
CN112956664A (zh) * | 2021-03-27 | 2021-06-15 | 黑龙江中医药大学 | 一种有助于改善睡眠功能的复合型果糕及其制备方法 |
CN113730511A (zh) * | 2021-09-17 | 2021-12-03 | 吉首大学 | 一种安神助眠的杜仲雄花配方组合物及其应用 |
CN114190505A (zh) * | 2021-12-15 | 2022-03-18 | 哈尔滨健领医疗科技有限公司 | 一种助眠固体饮料及其制备方法 |
CN116474060A (zh) * | 2022-01-13 | 2023-07-25 | 青岛百食膳康中医药科技有限公司 | 一种平衡阴阳改善睡眠的中药组合物、产品及其制备方法和应用 |
CN115521883A (zh) * | 2022-02-16 | 2022-12-27 | 广东益可维生物技术有限公司 | 一种具有缓解压力和改善睡眠功能的益生菌 |
CN115521883B (zh) * | 2022-02-16 | 2024-02-20 | 广东益可维生物技术有限公司 | 一种具有缓解压力和改善睡眠功能的益生菌 |
Also Published As
Publication number | Publication date |
---|---|
CN107126485B (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107126485A (zh) | 一种辅助改善睡眠的中药组合物及其制备方法和应用 | |
CN102078520A (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN103432475B (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
CN103041209B (zh) | 一种治疗肾阴虚的中药制剂及其制备方法 | |
CN102988703A (zh) | 一种治疗肾阳虚的中药制剂及其制备方法 | |
CN107853517B (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN106214964A (zh) | 安神的中药制剂 | |
CN103520505A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104825914A (zh) | 一种辅助治疗乳腺癌症的中药制剂 | |
CN101700336B (zh) | 一种治疗颅脑外伤后遗性头痛的中药制剂及其制备方法 | |
CN106520487A (zh) | 一种有助于睡眠的保健酒及其制备方法 | |
CN108478714A (zh) | 一种儿科自闭症康复治疗辅助用中药组合物 | |
CN1142785C (zh) | 抗疲劳胶囊 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104324134B (zh) | 一种改善微循环的中药组合物及其制备方法 | |
CN103301341A (zh) | 一种治疗缺血性脑中风的中药组合物 | |
CN106361976A (zh) | 一种安神助眠养颜复方制剂及其制备方法 | |
CN113632979A (zh) | 一种男女通用的四季养生饮料及其制备方法 | |
CN107875256B (zh) | 一种治疗失眠症的壮药穴位贴敷药贴及其制作方法 | |
CN112439038A (zh) | 一种快速改善睡眠的药物 | |
CN104688855B (zh) | 一种治疗慢性疲劳综合症的黄连阿胶组合物及其应用 | |
US11771727B2 (en) | Traditional Chinese medicine composition and product for improving sleep by balancing yin and yang, method for making the same and use thereof | |
CN112439037B (zh) | 一种缓解疲劳综合征的药物 | |
CN107048849A (zh) | 一种具有安神益智功效的中药床垫 | |
CN105434987A (zh) | 一种治疗脑梗塞的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |